1. Makhoul M, Bitton-Worms K, Adler Z, Saeed A, Cohen O, Bolotin Gv(2019). Extracorporeal Membrane Oxygenation
(ECMO)-A Lifesaving Technology. Review and Single-center Experience. Rambam Maimonides medical journal, 10(2), e0013. https://doi.org/10.5041/RMMJ.10363
2. Bertini P, Guarracino F, Falcone M, et al. ECMO in COVID-19 Patients: A Systematic Review and Meta-analysis.
J Cardiothorac Vasc Anesth. 2022;36(8 Pt A):2700-2706. doi:10.1053/j.jvca.2021.11.006
INDICATIONS FOR USE:
The Novalung® System is indicated for long-term (>6 hours) respiratory/cardiopulmonary support that provides assisted extracorporeal circulation and physiologic gas exchange (oxygenation and CO2 removal) of the patient’s blood in adults with acute respiratory failure or acute cardiopulmonary failure, where other available treatment options have failed, and continued clinical deterioration is expected or the risk of death is imminent. These may include: • Failure to wean from cardiopulmonary bypass following cardiac surgery in adult patients • ECMO-assisted cardiopulmonary resuscitation in adults
CAUTION: Federal (US) law restricts these devices to sale by or on the order of a physician.
NOTE: Read the Instructions for Use for safe and proper use of these devices. The Indications for Use for this device can be found at fmcna.com/products/indications-safety-and-warnings.
© 2022 Fresenius Medical Care. All Rights Reserved. Fresenius Medical Care, the triangle logo, and Novalung are trademarks of Fresenius Medical Care Holdings, Inc. or its affiliated companies. All other trademarks are the property of their respective owners. P/N 105248-01 Rev A 10/2022